Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 2/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13412948 | 0.88 | DRD2 (0.36) | DRD3DRD2SIGMAR1OPRD1 | |
| SCHEMBL19634914 | 0.82 | GNAI3 (0.41) | GNAI3GNAO1GNAI1DRD3DRD2 | |
| SCHEMBL13412945 | 0.79 | KDM4E (0.34) | SMN1; SMN2 | |
| SCHEMBL10175178 | 0.79 | MAOB (0.47) | GNAI3GNAO1GNAI1DRD3DRD2 | |
| SCHEMBL18536496 | 0.78 | — | — | |
| SCHEMBL5475889 | 0.78 | ALOX15 (0.52) | SIGMAR1 | |
| SCHEMBL7991668 | 0.77 | GNAI3 (0.48) | GNAI3GNAO1GNAI1DRD3SIGMAR1 | |
| SCHEMBL19630044 | 0.77 | GNAI3 (0.48) | GNAI3GNAO1GNAI1DRD3SIGMAR1 | |
| SCHEMBL4396763 | 0.76 | GNAI3 (0.42) | GNAI3GNAO1GNAI1DRD3DRD2 | |
| SCHEMBL6806026 | 0.76 | GNAI3 (0.42) | GNAI3GNAO1GNAI1DRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100055183-A1 | TRIMEPRAZINE AND ETHOPROPAZINE DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100055183-A1 | TRIMEPRAZINE AND ETHOPROPAZINE DERIVATIVES FOR PROMOTING BONE GROWTH | IGFBP5, BMP2, HGF | GNAI3 3072/4885GNAO1 3528/4885GNAI1 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.